Search results
Results from the WOW.Com Content Network
On 29 June 2021, the director of the Gamaleya Institute, Denis Logunov, said that Sputnik V is about 90% effective against the Delta variant. [ 81 ] On July 21, researchers from PHE published a study finding that the Pfizer vaccine was 93.7% effective against symptomatic disease from Delta after 2 doses, while the Astrazeneca vaccine was 67% ...
Sputnik V (Russian: Спутник V, the brand name from the Russian Direct Investment Fund or RDIF) or Gam-COVID-Vac (Russian: Гам-КОВИД-Вак, the name under which it is legally registered and produced [4]) is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and ...
The Delta variant, also known as B.1.617.2, G/452R.V3, 21A [75] or 21A/S:478K, [98] was a globally dominant variant that spread to at least 185 countries. [138] It was first discovered in India . Descendant of lineage B.1.617, which also includes the Kappa variant under investigation, it was first discovered in October 2020 and has since spread ...
Delta (B.617.2) First identified in India in late 2020, the delta variant soon spread across the globe. It became the dominant variant of SARS-CoV-2 until the emergence of omicron in December 2021.
It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). [3] The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. [ 4 ]
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19. [4]
There are many thousands of variants of SARS-CoV-2, which can be grouped into the much larger clades. [142] Several different clade nomenclatures have been proposed. Nextstrain divides the variants into five clades (19A, 19B, 20A, 20B, and 20C), while GISAID divides them into seven (L, O, V, S, G, GH, and GR).
A phase 3 clinical trial with 25,798 participants found that the vaccine is 64% (95% CI, 29 – 82%) effective against asymptomatic cases, 78% (65 – 86%) effective against symptomatic disease, 93% (57 – 100%) effective against severe disease, and 65% (33 – 83%) effective against the Delta variant.